Karen Cross - MIMOSA Diagnostics, Private Partnering Interview at LSI USA ‘23


Karen Cross

Karen Cross

CEO, MIMOSA Diagnostics
MIMOSA has developed a tiny, hand-held device that democratizes the collection of tissue information in patients with peripheral vascular disease (PVD), wound care, diabetes, burns, and potential post-operative surgical complications.


Hi I'm Karen Cross. I'm the CEO and co founder of MIMOSA Diagnostics. But I'm also a surgeon, scientist, surfer, single mom and I'm a van enthusiast. MIMOSA Diagnostics is a classroom medical device that attaches to a cell phone or smartphone. And we measure non invasively skin injuries. It's the first handheld portable imaging device for skin injuries. Not only that these images upload to a web portal for remote monitoring and viewing. What you might not know about skin injuries is that they happen every day in the healthcare system. And they happen from little babies as well as to our elderly population or what we call cradle to grave. So things like peripheral vascular disease, so poor circulation in your legs, if you have diabetes, or a bedsore or pressure injury, they also happen in the ICU, and we start to use some of these very fancy ventilators. So MIMOSA is actually FDA cleared for anything where tissue compromised or tissue injury needs to be measured. So we have brought indications and therefore broad utilization. The novel thing as well about this camera, if I could just tell you is that most of these technologies are a class of technology is called optical technologies. Most technologies in this space are only good for Caucasian skin, we are best in class, because we can measure melanin, and it's so it's good for all people. So it's not just for Caucasians buffer any skin tone. Not only that, because of our remote monitoring platform, we're able to monitor people in rural or remote places. So that being able to use that asynchronous telemedicine to triage patients earlier and get them the help they need in real time. Firstly, as a female CEO, definitely it's a different experience. But I was a plastic surgeon before I sort of started this as well as a PhD in engineering. During that time, again, I'm older than I look, I broke down a lot of barriers for females and surgery, females in science and engineering. And now as a med tech CEO, I'm very proud to say that 50% of my company are women. Also, we are a diverse company. And we believe in the vision and the vision of our team. So our team is a diverse team that believes and has the passion for solving this problem. So not only do we aim to create equity in the healthcare system with the device, and with the platform technology, we also aim to change the med tech space by creating equity within our own company. So classically, again, coming from the surgical field, there's lots of papers that have been published to show that women don't make as much money as men. So we'll use this example, what we've done is something that we call open compensation, where we're able to bridge the gender pay gap where women make the same salary as men. That's the first way that we've started in step one, but it is a mission and vision of our company to make that change. And I believe we can do it in med tech, which classically, is a very male dominated field. MIMOSA is a handheld medical imaging device. It's a classroom medical device that's FDA cleared, it's portable, it's magnetic, and it snaps onto the back of a cell phone, you literally load the app on the phone, it's a camera app. Again, we're looking at my hand, we're gonna fold to start the capture, you put the little flower essentially, we look if it's too far, the camera's gonna tell you it's too far. If it's too close, it tells you it's too close. And you're just waiting for it to be in the good range to take that picture. The reason for this is we're sampling the lighting conditions and temperature in the room so we can give you a very accurate medical grade image. Normally, these types of cameras would be 14 feet tall and 200 pounds to give you the same quality of image. When we click on the image up yourself red is good blue is bad, you can see that I'm well oxygenated, so I have good perfusion to my hand. Anything above 50% means that that tissue is viable, as well we provide the thermal image and again, although we're in California, I am a little cold and you can see that in my fingers. And then finally we provide a visual light image. The visual light image is not meant to be that digital photo, but meant to be a guideline for some of the artificial intelligence and machine learning we're doing with respect to reconstruction of these images within the web portal. We're really excited to be at LSI we are fully capitalized company and generating revenue but looking for our nest off opportunity with investors for our next round of funding. Also looking for strategic partners in our space, which will be one carrier peripheral vascular disease to can help that can help us scale and accelerate our growth.

LSI USA '24 is filling fast. Secure your spot today to join Medtech and Healthtech leaders in Dana Point.


Share this video

Companies We Work With